NCT07201194 Holistic Acupuncture for Patients With Chemotherapy Induced Nausea
| NCT ID | NCT07201194 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vejle Hospital |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-11-17 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone. A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone. The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment
Eligibility Criteria
Inclusion criteria * ≥ 18 years of age * Undergoing chemotherapy and experiencing nausea despite adherence to the prescribed antiemetic regimen * Understands and speaks Danish * Written and orally informed consent * Planned for treatment every 14 days * At least two chemotherapy cycles planned at the time of inclusion Exclusion Criteria: * Brain metastases * Performance status \>2
Contact & Investigator
Mette Stie, Phd
PRINCIPAL INVESTIGATOR
Department of Oncology, Lillebaelt Hospital, Vejle
Frequently Asked Questions
Who can join the NCT07201194 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07201194 currently recruiting?
Yes, NCT07201194 is actively recruiting participants. Contact the research team at mette.stie@rsyd.dk for enrollment information.
Where is the NCT07201194 trial being conducted?
This trial is being conducted at Vejle, Denmark.
Who is sponsoring the NCT07201194 clinical trial?
NCT07201194 is sponsored by Vejle Hospital. The principal investigator is Mette Stie, Phd at Department of Oncology, Lillebaelt Hospital, Vejle. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.